Trial Profile
A Randomized Double-Blind, Placebo- and Active-Control, Parallel-Arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Tapentadol (Primary) ; Oxycodone
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 21 May 2011 Results from a pooled analysis (700020566, 700023303 and 700058693) of a subset of patients aged at least 75 years were presented at the 30th Annual Scientific Meeting of the American Pain Society.
- 02 Sep 2010 Results from a pooled analysis (700020566, 700023303 and 700058693) were reported at the 13th World Congress on Pain.
- 30 Aug 2010 Results have been published in the journal "Clinical Drug Investigation" according to an Ortho McNeil Janssen Pharmaceutical media release. Results are discussed further within the media release.